TheStreet cut shares of SurModics Inc. (NASDAQ:SRDX) from a buy rating to a hold rating in a report published on Monday.

SRDX has been the topic of several other research reports. Zacks Investment Research lowered SurModics from a buy rating to a hold rating in a report on Friday, October 21st. Barrington Research lowered SurModics from an outperform rating to a market perform rating in a report on Monday, November 21st. Finally, Sidoti lowered SurModics from a buy rating to a neutral rating and set a $33.00 price objective on the stock. in a report on Thursday, October 6th.

SurModics (NASDAQ:SRDX) opened at 23.95 on Monday. SurModics has a 12-month low of $17.45 and a 12-month high of $30.75. The firm has a market cap of $313.46 million, a PE ratio of 31.51 and a beta of 0.98. The company has a 50-day moving average price of $26.64 and a 200-day moving average price of $26.23.

SurModics (NASDAQ:SRDX) last issued its quarterly earnings data on Wednesday, November 16th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.17. The company had revenue of $18.20 million for the quarter, compared to analyst estimates of $16.09 million. SurModics had a return on equity of 15.98% and a net margin of 13.99%. The business’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same quarter last year, the company posted $0.30 earnings per share. On average, equities analysts predict that SurModics will post $1.04 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This report was originally published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international copyright law. The original version of this report can be accessed at

In related news, CEO Gary R. Maharaj sold 5,000 shares of the firm’s stock in a transaction dated Monday, November 7th. The stock was sold at an average price of $25.22, for a total transaction of $126,100.00. Following the transaction, the chief executive officer now owns 130,207 shares of the company’s stock, valued at $3,283,820.54. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 7.20% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in SRDX. First Quadrant L P CA raised its position in SurModics by 9.4% in the third quarter. First Quadrant L P CA now owns 4,374 shares of the company’s stock worth $132,000 after buying an additional 374 shares in the last quarter. Condor Capital Management bought a new position in SurModics during the third quarter worth about $202,000. Arizona State Retirement System bought a new position in SurModics during the third quarter worth about $204,000. Bank of Montreal Can bought a new position in SurModics during the second quarter worth about $190,000. Finally, Meristem LLP bought a new position in SurModics during the third quarter worth about $247,000. 88.55% of the stock is currently owned by hedge funds and other institutional investors.

SurModics Company Profile

SurModics, Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company is focused on to transform its medical device business from being a provider of coating technologies to offering whole product solutions to medical device customers.

5 Day Chart for NASDAQ:SRDX

Receive News & Ratings for SurModics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SurModics Inc. and related companies with's FREE daily email newsletter.